libervant

Libervant is a buccal film formulation of diazepam, a benzodiazepine anticonvulsant, developed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters or acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in pediatric patients with epilepsy aged 2 to 5 years. The film is placed on the inside of the cheek (buccally), where it adheres and dissolves quickly to deliver diazepam systemically. Diazepam acts primarily by binding to the benzodiazepine site on the GABA\(_A\) receptor, enhancing GABA-mediated inhibitory neurotransmission in the central nervous system. Libervant was developed as an alternative to rectal gel and nasal spray formulations for rescue therapy in seizure clusters, offering improved ease of use and non-invasive administration. It received FDA approval in April 2024 for pediatric patients ages 2–5 with seizure clusters[3][5][8][10].

Brand names

Libervant

Other names

diazepam buccal film